Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Accured Expenses (2016 - 2025)

Avalo Therapeutics' Change in Accured Expenses history spans 12 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 435.54% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $6.7 million, up 699.64%, while the annual FY2025 figure was $6.7 million, 699.64% up from the prior year.
  • Change in Accured Expenses reached $5.4 million in Q4 2025 per AVTX's latest filing, up from $1.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.4 million in Q4 2025 to a low of -$4.9 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$193950.0, with a median of -$587000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: soared 1314.08% in 2021, then tumbled 726.21% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $646000.0 in 2021, then tumbled by 175.54% to -$488000.0 in 2022, then tumbled by 96.72% to -$960000.0 in 2023, then surged by 204.06% to $999000.0 in 2024, then skyrocketed by 435.54% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Change in Accured Expenses are $5.4 million (Q4 2025), $1.0 million (Q3 2025), and $2.0 million (Q2 2025).